Deleterious effects of selective serotonin reuptake inhibitor treatment on semen parameters in patients with lifelong premature ejaculation
International Journal of Impotence Research: The Journal of Sexual Medicine, Exclusive Author Commentary

Koyuncu H et al. – Although no drug for premature ejaculation (PE) has been approved by regulatory bodies, chronic selective serotonin reuptake inhibitors proved to be effective in treating lifelong PE. Despite the rising use and known effects of antidepressants on ejaculation, only a few reports have evaluated the impact of these drugs on the male fertility.

Following View Author Commentary page

Premature ejaculation (PE), the most common sexual dysfunctions in men and is characterized by the loss or absence of ejaculatory control. The prevalence rate of PE has been reported to be between 21% to 31% and is recognized to impact on a man’s life in many ways, such as reducing self-esteem, affecting interpersonal relationships, causing anxiety, embarrassment, depression and reducing overall quality of life. Recent guidelines have proposed chronic use of SSRIs (e.g. fluoxetine, sertraline, paroxetine and citalopram) for the treatment of lifelong PE. The SSRIs block 5-hydroxytriptamine (5-HT) transporter mechanisms and thereby increase 5-HT within the synapses. This in turn activates 5-HT1A and 5-HT1B receptors resulting in inhibition of serotonin release into the synapse. With chronic administration of SSRIs, the receptors become desensitized and there is a reduction of inhibitory action on serotonin release. The end result is more serotonin release into the synapse, of the ejaculatory set point, and delay in the ejaculatory reflex. In spite of their efficacy, adverse effects are the major drawback in chronic use of SSRIs in PE patients. Well known adverse effects of SSRIs include sexual dysfunction (sexual desire and arousal difficulties, anejaculation, absent and delayed orgasm), dizziness, nausea, constipation, insomnia and fatigue. Few studies have addressed the impact of SSRIs on spermatozoal function and fertility. Published data clearly show that chronic SSRI treatment has a detrimental effect on spermatogenesis and sperm transport, damages the sperm membrane, alters sperm DNA and has an impact on hormonal homeostasis. These effects may not be important for men undergoing treatments for severe depression; however they must be taken into consideration when SSRIs are administered to a sexually active man with PE. In summary, the potential advers effects of SSRIs on male fertility needs to be considered when treating a young man with PE.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Urology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Urology Articles

1 Who dies from prostate cancer? Prostate Cancer & Prostatic Diseases, October 17, 2014    Clinical Article

2 The use of metformin in patients with prostate cancer and the risk of death Cancer Epidemiology, Biomarkers & Prevention, September 22, 2014    Clinical Article

3 Diethylstilboestrol (1 mg) in the management of castration-resistant prostate cancer Urologia Internationalis, October 21, 2014    Clinical Article

4 Daily aspirin use and prostate cancer–specific mortality in a large cohort of men with nonmetastatic prostate cancer Journal of Clinical Oncology, October 24, 2014    Clinical Article

5 The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml Cancer Epidemiology, September 26, 2014    Clinical Article

6 Prevention and early detection of prostate cancer The Lancet Oncology, October 7, 2014    Review Article

7 Highly-trained dogs' olfactory system detects prostate cancer in urine samples The Journal of Urology, October 20, 2014    Clinical Article

8 Concordance between biopsy and radical prostatectomy specimen gleason score in internal and external pathology facilities Anticancer Research, October 22, 2014    Clinical Article

9 Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: Initial results from the cryo on-line data registry The Prostate, October 9, 2014    Clinical Article

10 Particle radiotherapy for prostate cancer International Journal of Urology, October 23, 2014    Review Article

11 Prostate cancer incidence, clinical stage and survival in relation to obesity: A prospective cohort study in Denmark International Journal of Cancer, October 2, 2014    Clinical Article

12 Biologic differences between peripheral and transition zone prostate cancer The Prostate, October 28, 2014    Clinical Article

13 Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation The Journal of Urology, October 30, 2014    Clinical Article

14 Smoking and risk of low- and high-grade prostate cancer: Results from the REDUCE study Clinical Cancer Research, September 19, 2014    Clinical Article

15 Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA) The Prostate, October 1, 2014    Clinical Article

16 Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy The Prostate, October 29, 2014    Clinical Article

17 Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: A systematic review with meta-analyses Clinical Oncology, August 8, 2014    Evidence Based Medicine    Review Article

18 Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer Urologic Oncology: Seminars and Original Investigations, October 16, 2014    Clinical Article

19 Stereotactic body radiation therapy for prostate cancer: Review of experience of a multicenter phase I/II dose escalation study Frontiers in Oncology, October 13, 2014    Review Article    Clinical Article

20 Silodosin for the treatment of clinical benign prostatic hyperplasia: Safety, efficacy, and patient acceptability Full Text Research and Reports in Urology, October 6, 2014    Free full text    Review Article

Indexed Journals in Urology: Urology, Journal of Urology, European Urology, The Prostatemore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close